Targeting PD-L1 in non-small cell lung cancer using CAR T cells

Abstract Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) deve...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ming Liu, Xu Wang, Wei Li, Xinfang Yu, Pedro O. Flores-Villanueva, Zijun Y. Xu‐Monette, Ling Li, Mingzhi Zhang, Ken H. Young, Xiaodong Ma, Yong Li
Formato: Artigo
Idioma:inglés
Publicado: 2020
Acceso en liña:https://doi.org/10.1038/s41389-020-00257-z
https://www.nature.com/articles/s41389-020-00257-z.pdf
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!